Health Trials

Gastroenteropancreatic Neuroendocrine Tumor Disease

2

Review clinical trials related to Gastroenteropancreatic Neuroendocrine Tumor Disease. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.

The primary objectives are to determine the recommended Phase 2 dose (RP2D) and optimal treatment regimen, characterize safety and tolerability, and evaluate preliminary efficacy of RYZ401 in subjects with NETs and other selected solid tumors expressing SSTRs.

Participants needed: 104
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: RayzeBio, Inc.Updated: Jun 9, 2026Locations: 9
Eligibility criteria

At least 18 years old at the time of signing the main study informed consent for... [+4]

Prior RPT, including Lu-177. [+7]

Read more
Status: Recruiting

Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy

This study aims to determine the safety, pharmacokinetics (PK) and recommended Phase 3 dose (RP3D) of RYZ101 in Part 1, and the safety, efficacy, and PK of RYZ101 compared with investigator-selected standard of care (SoC) therapy in Part 2 in subjects with inoperable, advanced, well-differentiated, somatostatin receptor expressing (SSTR+) gastroenteropancreatic neuroendocrine tumors (GEP-NETs) that have progressed following treatment with Lutetium 177-labelled somatostatin analogue (177Lu-SSA) therapy, such as 177Lu-DOTATATE or 177Lu-DOTATOC (177Lu-DOTATATE/TOC), or 177Lu-high affinity \[HA\]-DOTATATE.

Participants needed: 338
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: RayzeBio, Inc.Updated: Mar 30, 2026Locations: 54
Eligibility criteria

Histologically proven, Grade 1-2 well differentiated, inoperable, advanced GEP-N... [+12]

Read more